Back to results
US 12,673,043 B2Granted
Use of inhibitors of the activator protein 1 (AP-1) for preventing adhesions
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsMichael T. Longaker, Gerlinde Wernig, Jeffrey A. Norton, Geoffrey Gurtner, Michael Januszyk, Deshka Foster, Malini Chinta
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation.
Claims10
A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions, the method comprising:
- administering topically to abdominal cavity of an abdominal surgery patient thereof an effective dose of a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, wherein the small molecule inhibitor is T-5224 (3-[5-(4-Cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy phenyl]propanoic acid).
A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions, the method comprising:
- administering topically to a surgical site or cavity of a subject in need thereof an effective dose of a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, wherein the small molecule inhibitor is T-5224 (3-[5-(4-Cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy]phenyl]propanoic acid).
A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions, the method comprising:
- administering topically to the abdominal cavity of a subject in need thereof an effective dose of a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, wherein the small molecule inhibitor is T-5224 (3-[5-(4-Cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy]phenyl]propanoic acid).
Dependencies are inferred from the claim text.